.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Merck
UBS
Dow
McKesson
Medtronic
McKinsey
Chubb
US Army
Baxter
Novartis

Generated: June 29, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,349,294

« Back to Dashboard

Which drugs does patent 8,349,294 protect, and when does it expire?


Patent 8,349,294 protects TOBI PODHALER and is included in one NDA.

This patent has one hundred and forty-nine patent family members in thirty-seven countries.

Summary for Patent: 8,349,294

Title:Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
Abstract: Microparticle compositions comprising metal ion-lipid complexes for drug delivery are described including methods of making the microparticle compositions and methods of treating certain conditions and disease states by administering the microparticle compositions. The metal ion-lipid complexes can be combined with various drugs or active agents for therapeutic administration. The microparticle compositions of the present invention have superior stability to other microparticle compositions resulting in a microparticle composition with longer shelf life and improved dispersability. The microparticle compositions of the present invention have a transition temperature (T.sub.g) of at least 20.degree. C. above the recommended storage temperature (Tst) for drug delivery.
Inventor(s): Dellamary; Luis A (San Marcos, CA), Riess; Jean (Falicon, FR), Schutt; Ernest G (San Diego, CA), Weers; Jeffry G (Belmont, CA), Tarara; Thomas E (Burlingame, CA)
Assignee: Novartis AG (Basel, CH)
Application Number:12/967,482
Patent Claim Types:
see list of patent claims
Composition; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Novartis
TOBI PODHALER
tobramycin
POWDER;INHALATION201688-001Mar 22, 2013RXYesYes8,349,294► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,349,294

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,790,145Respiratory dispersion for metered dose inhalers► Subscribe
7,871,598Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use► Subscribe
9,439,862Phospholipid-based powders for drug delivery► Subscribe
6,630,169 Particulate delivery systems and methods of use► Subscribe
7,442,388Phospholipid-based powders for drug delivery► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,349,294

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Denmark1019022► Subscribe
Japan2003525841► Subscribe
Iceland5415► Subscribe
Iceland2154► Subscribe
South Korea20030038541► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Dow
Fish and Richardson
Novartis
Argus Health
Farmers Insurance
Julphar
Fuji
Medtronic
US Army
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot